Since its establishment in 2000, Lixin pharmaceutical has adhered to the goal of becoming a global standardized API and important intermediate leading the market, adhered to relying on scientific and technological innovation to drive the company, followed the path of sustainable development, gradually formed an API product system in the fields of anti-tumor, cardiovascular, antiplatelet and treatment of Alzheimer's disease, and become a high-quality supplier for many pharmaceutical companies around the world, It has established long-term cooperative relations with many famous pharmaceutical companies at home and abroad to achieve win-win cooperation. Lixin pharmaceutical focuses on the in-depth research, development and production of products in the field of characteristic APIs and APIs for major diseases. Adhering to the scientific, rigorous and standardized corporate culture, advocating the spirit of innovation, and paying attention to the development and application of original technology with safety, environmental protection, low consumption and high quality, Lixin pharmaceutical has more than 30 international invention patents in China, the United States, Europe and other regions, An independent intellectual property system has been formed. Lixin pharmaceutical not only provides high-quality API and key intermediates, but also provides integrated technical solutions including API process development, quality research, crystal form and particle size research, standard and impurity control according to customers' needs. The company has obtained 3 American DMF documents, 3 CEP certificates, 5 nmpa new drug certificates and 8 domestic GMP certificates. At the same time, more than 20 products are under project approval, R & D and registration at home and abroad. It has laid a solid foundation for the rapid, efficient and sustainable development of the company. Lixin pharmaceutical adheres to the standard and strict GMP management system of the EU, the United States and China, and continues to improve and pursue excellence. There is a 12000m2 cGMP API production base in Suzhou high tech Zone, with multiple GMP workshops, chemical synthesis workshops and perfect supporting facilities. It has passed nmpa, FDA, EDQM and EMA certification for many times. Covering an area of 150 mu, Shandong Lixin pharmaceutical project, a characteristic API production base with a total investment of 360 million yuan and in line with European and American specifications, has begun construction and will be put into formal production in 2018. At that time, the company will complete the international layout of the industrial chain.